Pharvaris has announced the start of enrollment in CHAPTER-3, a Phase 3 study assessing the efficacy of deucrictibant for preventing hereditary angioedema (HAE) attacks, with topline results expected ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback